Drug Profile
AVX 601
Alternative Names: AVX601; Cytomegalovirus vaccine - AlphaVax/GSKLatest Information Update: 10 Jul 2023
Price :
$50
*
At a glance
- Originator AlphaVax
- Class Antivirals; Cytomegalovirus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cytomegalovirus infections
Most Recent Events
- 22 Feb 2021 Phase-II development for Cytomegalovirus infections (Prevention) is ongoing in the US (IM) (AlphaVax pipeline, February 2021)
- 22 Feb 2021 Phase-II development for Cytomegalovirus infections (Prevention) is ongoing in the US (SC) (AlphaVax pipeline, February 2021)
- 07 May 2018 Phase-II clinical trials in Cytomegalovirus infections (Prevention) in USA (IM) (Alphavax pipeline, May 2018)